Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2016) 128 (22): 2816.

https://doi.org/10.1182/blood.V128.22.2816.2816

Published: 2016

Journal Articles

Direct Conversion of Adult Endothelial Cells into Immunecompetent Long-Term Engraftable Clinically Scalable Hematopoietic Stem Cells: Pathway to Therapeutic Translation

Raphael Lis, PhD, Charles Harrasch, Michael Gustave Poulos, PhD, Jose Gabriel Duran, William Schachterle, PhD, Michael Ginsberg, PhD, Arash Rafii, Koji Shido, Nancy A. Speck, PhD, Jason M. Butler, PhD, Joseph M. Scandura, MD PhD, Shahin Rafii

Blood (2016) 128 (22): 372.

https://doi.org/10.1182/blood.V128.22.372.372

Published: 2016

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Hesam Hekmatjou, MD, Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sangmin Lee, MD, Pinkal Desai, MD, Joseph M. Scandura, MD PhD, Sandra Allen-Bard, ANP, BS, BSN, MSN, NP, Paul Christos, DrPH, Richard T. Silver, MD, Eric J. Feldman, MD

Blood (2014) 124 (21): 1811.

https://doi.org/10.1182/blood.V124.21.1811.1811

Published: 2014

Journal Articles

Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

John N. Allan, MD, Gail J. Roboz, MD, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Ellen K. Ritchie, MD, Linda Lam, Wen Xie, Hsiao-Ting Hsu, MS, Duane C Hassane, PhD, Monica L. Guzman, PhD

Blood (2014) 124 (21): 1041.

https://doi.org/10.1182/blood.V124.21.1041.1041

Published: 2014

Journal Articles

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Ellen K. Ritchie, MD, Danielle C. Marshall, B.A., Molly D. Greenberg, B.S., Tania J. Curcio, R.N, Ashley E. Giambrone, PhD, Paul Christos, DrPH, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Gail J. Roboz, MD

Blood (2014) 124 (21): 3689.

https://doi.org/10.1182/blood.V124.21.3689.3689

Published: 2014

Journal Articles

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

Gail J. Roboz, MD, Joseph M. Scandura, MD, PhD, Ellen Ritchie, MD, Yulia Dault, RN, Linda Lam, Wen Xie, Hsiao-Ting Hsu, Danielle Marshall, Paul J Christos, Cindy Ippoliti, Eric J. Feldman, MD, Monica L. Guzman, PhD

Blood (2013) 122 (21): 621.

https://doi.org/10.1182/blood.V122.21.621.621

Published: 2013

Journal Articles

TGFβ Restores Hematopoietic Homeostasis After Chemotherapy.

Fabienne A. Brenet, PhD, Pouneh Kermani, PhD, Shahin Rafii, MD, Joseph M. Scandura, MD, PhD

Blood (2012) 120 (21): 2344.

https://doi.org/10.1182/blood.V120.21.2344.2344

Published: 2012

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

Usama Gergis, MD, Gail J. Roboz, MD, Ellen Ritchie, MD, Joseph M. Scandura, MD, PhD, Karen-Sue B. Carlson, MD, PhD, Tsiporah B. Shore, MD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Roger N Pearse, MD, PhD, June Greenberg, Tania J Curcio, R.N, Cindy Ippoliti, PharmD, Marshall McKenna, Eric J Feldman, MD

Blood (2011) 118 (21): 3030.

https://doi.org/10.1182/blood.V118.21.3030.3030

Published: 2011

Journal Articles

CDKN1C Modulates the Stress-Reponse of Hematopoietic Stem Cells Rendering Hematopoiesis Resistant to Chemotherapeutics

Fabienne A. Brenet, PhD, Joseph M. Scandura, MD, PhD

Blood (2010) 116 (21): 3162.

https://doi.org/10.1182/blood.V116.21.3162.3162

Published: 2010

Journal Articles

A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.

Usama Gergis, MD, Ellen Ritchie, MD, Gail J. Roboz, MD, Joseph M. Scandura, MD, PhD, Sebastian Mayer, MD, Tomer M Mark, MD, MSc, Tsiporah B. Shore, MD, Usama Wissa, MD, Eric J Feldman, MD

Blood (2010) 116 (21): 1334.

https://doi.org/10.1182/blood.V116.21.1334.1334

Published: 2010

Journal Articles

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Ellen K Ritchie, MD, Jon Arnason, MD, Eric J. Feldman, MD, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Joseph M. Scandura, MD, PhD, Gail Roboz, MD

Blood (2009) 114 (22): 2063.

https://doi.org/10.1182/blood.V114.22.2063.2063

Published: 2009

Journal Articles

Evaluation of Alternative, “Low-intensity” Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML).

Eric J. Feldman, MD, Ellen Ritchie, MD, Usama Gergis, MD, Sebastian Mayer, MD, Joseph M. Scandura, MD, PhD, Paul J. Christos, PhD, Usama Wissa, MD, Gail J. Roboz, MD

Blood (2009) 114 (22): 2066.

https://doi.org/10.1182/blood.V114.22.2066.2066

Published: 2009

Journal Articles

Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment.

Fabienne Brenet, Ph.D., Michelle Moh, MS, Patricia Funk, BS, Daoqui You, MS, Agnes J. Viale, Ph.D., Nicholas D. Socci, PhD, Joseph M. Scandura, MD, PhD

Blood (2009) 114 (22): 591.

https://doi.org/10.1182/blood.V114.22.591.591

Published: 2009

Journal Articles

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Joseph M. Scandura, MD, PhD, Gail J. Roboz, MD, Michelle Moh, MS, Jahar R Bose, Usama S Gergis, MD, Sebastian A Mayer, MD, Cindy Ippoliti, PharmD, Curcio J Tania, RN, Ellen K Ritchie, MD, Eric J. Feldman, MD

Blood (2009) 114 (22): 3079.

https://doi.org/10.1182/blood.V114.22.3079.3079

Published: 2009

NARROW

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Direct Conversion of Adult Endothelial Cells into Immunecompetent Long-Term Engraftable Clinically Scalable Hematopoietic Stem Cells: Pathway to Therapeutic Translation

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML

TGFβ Restores Hematopoietic Homeostasis After Chemotherapy.

A Novel Sequential Treatment Utilizing CPX-351 As Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory Leukemia

CDKN1C Modulates the Stress-Reponse of Hematopoietic Stem Cells Rendering Hematopoiesis Resistant to Chemotherapeutics

A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia.

Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia.

Evaluation of Alternative, “Low-intensity” Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML).

Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment.

Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only